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Abstract
Synucleinopathies [Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA)]
share filamentous α-synuclein assemblies in nerve cells and glial cells. We compared the abilities of brain extracts
from MSA and PD patients to induce neuronal α-synuclein assembly and neurodegeneration following intracerebral
injection in heterozygous mice transgenic for human mutant A53T α-synuclein. MSA extracts were more potent
than PD extracts in inducing α-synuclein assembly and in causing neurodegeneration. MSA assemblies were
Campbell-Switzer- and Gallyas-silver-positive, whereas PD assemblies were only Campbell-Switzer-positive, in
confirmation of previous findings. However, induced α-synuclein inclusions were invariably Campbell-Switzer-
positive and Gallyas-negative, irrespective of whether MSA or PD brain extracts were injected. The α-synuclein
inclusions of non-injected homozygous mice transgenic for A53T α-synuclein were also Campbell-Switzer-positive
and Gallyas-negative. These findings demonstrate that transgene expression and its intracellular environment
dominated over the silver staining properties of the conformers of assembled α-synuclein.
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Introduction
The ordered assembly of α-synuclein into abnormal fila-
ments defines a group of neurodegenerative diseases
called synucleinopathies [18]. α-Synuclein was linked to
Parkinson’s disease (PD), when a dominantly inherited
missense mutation (A53T) in SNCA, the α-synuclein
gene, was found to cause a familial form of PD [39].
Subsequently, genome-wide association studies also
identified α-synuclein as a significant risk factor for idio-
pathic PD [32]. α-Synuclein is the major component of
Lewy bodies and Lewy neurites, the intraneuronal fila-
mentous assemblies found in all patients with PD, with
or without dementia, and in patients with dementia with
Lewy bodies (DLB) [44, 45]. α-Synuclein not only accu-
mulates in Lewy pathology, but it can also template its
assembly. Injection of misfolded α-synuclein induces
assembly of endogenous protein into phosphorylated
assemblies that resemble Lewy bodies [26, 31]. Neurons
bearing Lewy bodies eventually die [19, 33].
Filamentous inclusions of multiple system atrophy
(MSA) are also made of α-synuclein [43, 47, 51]. MSA is
more aggressive than PD and DLB, with an interval
between diagnosis and death of approximately 9
years [11]. The defining lesion of MSA is the presence of
α-synuclein inclusions in oligodendrocytes, the majority of
which are in the form of cytoplasmic inclusions [glial cyto-
plasmic inclusions (GCIs) or Papp-Lantos inclusions [34,
35]]. Smaller numbers of filamentous α-synuclein
inclusions are also present in the nuclei, cytoplasm and
processes of some neurons [8]. Inclusions comprise α-
synuclein phosphorylated at S129 [1, 13].
Much previous work on seeded aggregation used M83
mice, which are transgenic for human mutant A53T α-
synuclein, under the control of the prion protein promoter
[16]. Homozygous mice (M83+/+) develop abundant
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neuronal inclusions made of filamentous pS129 α-
synuclein and neurodegeneration when aged 8–16
months, whereas heterozygotes (M83+/−) show no α-
synuclein inclusions or neurodegeneration until 20
months of age. Inclusions are most abundant through-
out spinal cord and hindbrain, followed by midbrain,
thalamus and hypothalamus.
Experimental studies established that the intracellular
milieu of oligodendrocytes is essential for the formation of
GCI-specific conformers of assembled α-synuclein [33].
Previous investigations using mouse models of seeded
pathology through intracerebral injections with brain sam-
ples from patients with either PD or MSA showed that
MSA extracts were capable of inducing neuronal α-
synuclein pathology in transgenic mice [40, 52]. Thus, ho-
mogenates from the brains of patients with MSA induced
the formation of abundant α-synuclein inclusions and
neurodegeneration characterized by motor symptoms in
M83+/− mice. In contrast, injection of brain homogenates
from the brains of PD patients failed to induce the forma-
tion of either α-synuclein inclusions or neurodegenera-
tion. These findings lent support to the view that different
conformers of assembled α-synuclein are typical of PD
and MSA.
Although the filamentous inclusions of MSA and PD
are made of modified, assembled α-synuclein, they can
be distinguished using silver staining, consistent with the
presence of distinct conformers [35, 49]. Thus, GCIs and
neuronal inclusions exhibit argyrophilia with both
Campbell-Switzer and Gallyas, whereas Lewy pathology
stains with Campbell-Switzer, but not Gallyas.
We injected brain homogenates from 7 MSA and 5 PD
cases, all neuropathologically confirmed, into the hippo-
campus and overlying cerebral cortex of M83+/− mice.
Thirty mice injected with MSA brain extracts developed
abundant neuronal α-synuclein inclusions and neurode-
generation, with an incubation time of 167 ± 17 days. The
same was true of 7 of 17 mice injected with PD extracts
(incubation time of 286 ± 62 days). By 18months of age, 5
additional mice had developed α-synuclein inclusions, in
the absence of neurodegeneration.
Inclusions were positive with Campbell-Switzer and
negative with Gallyas silver, irrespective of whether MSA
or PD extracts were injected. The same was true of assem-
bled recombinant α-synuclein, which induced the forma-
tion of abundant α-synuclein inclusions and caused
neurodegeneration (incubation time of 145 ± 10 days). α-
Synuclein inclusions of non-injected M83+/+ mice were
also Campbell-Switzer-positive and Gallyas-negative.
Materials and methods
Transgenic mice
The M83 transgenic mouse line, which expresses human
mutant A53T α-synuclein under the control of the mouse
prion protein promoter [16], was purchased from the
Jackson Laboratory (stock number 004479). Mice hetero-
zygous and homozygous for the transgene were used. All
experiments were carried out in compliance with the
Animals (Scientifc Procedures) Act of 1986 and were
approved by the local Animal Welfare and Ethical Review
Board.
Human brain tissues
Frozen brain tissues from neuropathologically confirmed
cases of MSA and PD were obtained from the Queen
Square Brain Bank for Neurological Disorders (London,
UK) and the tissue collection at Indiana University (In-
dianapolis, USA). Tissues were homogenised in
phosphate-buffered saline (PBS) (200 mg/ml), sonicated
(Misonix: output 2 for 5 × 0.9 s) and centrifuged in the
cold at 3000 g for 5 min. Supernatants were aliquoted,
snap frozen and stored at − 80 °C until use.
Recombinant human α-synuclein
Full-length human α-synuclein was expressed and
purified, as described [23, 53]. It was assembled into
filaments by incubating 400 μM at 37 °C for 48 h with
constant agitation at 450 rpm.
Intracerebral injection
Three-month-old heterozygous M83 mice were anaes-
thetised with isoflurane and injected unilaterally with
5 μl human brain extract or 5 μl assembled recombinant
human α-synuclein (400 μM), as described for tau
assemblies [6]; 2.5 μl were injected into the right hippo-
campus (A/P, − 2.5 mm; M/L, + 2.0 mm; D/V, − 2.0 mm)
and 2.5μl into the overlying cerebral cortex (A/P, − 2.5
mm; M/L, + 2.0 mm; D/V, − 1.0 mm) at a speed of
1.25 μl/min. Following injection, the needle was kept in
place for another 3 min. Mice were given analgesia
(Rimadyl, 4 mg/kg) prior to surgery and were placed on
a heat mat; their body temperatures were monitored
throughout surgery and they were placed in a heat cabi-
net after surgery to aid recovery.
Survival
Following stereotaxic brain injections, mice were moni-
tored weekly for signs of motor impairment. When they
reached hind limb paralysis, they were humanely killed
and their brains and spinal cords collected. Kaplan-
Meier survival curves were produced using Graphpad
Prism 7.
Dot blotting
The levels of α-synuclein phosphorylated at S129 were
determined by dot blotting (Minifold I Spot-Blot System,
GE Healthcare), using human brain samples diluted 1:
1000, and run in quadruplicate. Dried nitrocellulose
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membranes (Amersham) were blocked, incubated with a
polyclonal pS129 α-synuclein antibody (ab18467,
Abcam, 1:5000) for 3 h at room temperature, followed
by secondary antibody (1:4000) for 1 h. Chemilumines-
cence and ImageJ were used to quantify the signal. Phos-
phorylation of purified recombinant human α-synuclein
at S129 using casein kinase-2 (New England Biolabs)
was done as described [42]. Serial dilutions (0.5–3.5 ng)
were used as standard. The linear parts of the standard
curves were used to measure the concentrations of
pS129 α-synuclein.
Immunohistochemistry and silver staining
Mice were terminally anaesthetised and transcardially
perfused with 20 ml cold PBS, followed by 20ml 4%
paraformaldehyde in 0.1M phosphate buffer. Brains and
spinal cords were dissected and postfixed overnight.
Fixed tissues were paraffin-embedded and 8 μm sections
cut. Following deparaffinisation, the sections were
incubated in blocking buffer [PBS + 0.1% Triton X-100
(PBST) + 10% foetal calf serum] for 15 min at room
temperature, followed by an overnight incubation with
primary antibody specific for pS129 α-synuclein
(ab51253, Abcam, 1:5000 dilution) in blocking buffer.
After three rinses with PBST, the sections were incu-
bated with biotin-conjugated secondary anti-rabbit
antibody (1:200 dilution) for 1 h at room temperature.
The antigen was visualised with the Vector VIP substrate
kit (Vector Laboratories). Fixed, deparaffinised tissue
sections were stained using Campbell-Switzer [4, 5] or
Gallyas [6, 15] silver, as described. All sections were
counterstained with haematoxylin and coverslipped
using Pertex mounting medium.
Results
We homogenised and sonicated cerebellum (7 cases of
MSA) and substantia nigra (5 cases of PD) from neuro-
pathologically confirmed cases of disease (200mg/ml) and
injected 2.5 μl into the hippocampus and 2.5 μl into the
overlying cerebral cortex of heterozygous M83 mice trans-
genic for human mutant A53T α-synuclein. Recombinant
assembled human α-synuclein was used as a positive and
cerebellar extract from a neurologically normal individual
as a negative control. Upon development of hindlimb par-
alysis, the mice were culled, their brains and spinal cords
dissected and stained for pS129 α-synuclein, as well as
Campbell-Switzer and Gallyas silver. Mice without hind-
limb paralysis were culled at 18months of age.
Thirty heterozygous M83 mice were injected with cere-
bellar extract from 7 cases of MSA. All injected mice
developed hindlimb paralysis with an average incubation
time of 167 ± 17 days (Table 1; Fig. 1). Assembled α-
synuclein was detected in the central nervous system
(Figs. 4 and 5), with amounts and distributions similar to
those previously described for homozygous M83 mice
[16]. We injected 17 heterozygous M83 mice with
Table 1 Motor impairment of heterozygous mice transgenic for human mutant A53T α-synuclein following intracerebral injection of
brain extracts from multiple system atrophy (MSA)
Human brain extract Age at death Mice injected Mice with motor impairment Survival (days) SD
(1) MSA-P 68 10 10 168 21
(2) MSA-P 75 2 2 181 12
(3) MSA-P 82 3 3 166 28
(4) MSA-P 65 4 4 166 20
(5) MSA-P 83 4 4 168 19
(6) MSA-C 69 3 3 174 4
(7) MSA-C 60 4 4 152 23
Table 2 Motor impairment of heterozygous mice transgenic for human mutant A53T α-synuclein following intracerebral injection of
brain extracts from Parkinson’s disease (PD)
Human brain extract Age at death Mice injected Mice with
motor impairment
Survival (days) SD Survivors to 18 Mo Survivors with
assembled α-synclein
(1) PD 76 3 0 – – 3 2
(2) PD 83 4 4 288 79 – –
(3) PD 92 3 1 265 – 2 1
(4) PD 68 3 1 335 – 2 1
(5) PD 74 4 1 – – 3 1
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substantia nigra extract from 5 cases of PD. Only 7 mice
developed hindlimb paralysis, with an average incubation
time of 286 ± 62 days (Table 2; Fig. 1). Assembled α-
synuclein was detected in the central nervous system, with
a distribution similar to that seen in homozygous mice
(Figs. 4 and 5). However, the number of inclusions was ap-
proximately two-fold less. The remaining 10 mice were
culled at 18months of age. Five mice showed staining for
α-synuclein phosphorylated at S129, with a similar distri-
bution of pathology to that described in homozygous M83
mice, but significantly fewer inclusions in a given region.
As a positive control, 32 heterozygous M83 mice were
injected with 30 μg assembled recombinant human α-
synuclein. All mice developed hindlimb paralysis and ex-
tensive pS129-α-synuclein immunoreactivity, with an
average incubation time of 145 ± 10 days (Figs. 1, 4 and 5).
α
a
b
c
Fig. 1 Survival of heterozygous mice transgenic for human mutant A53T α-synuclein following intracerebral injection of (a) cerebellar extracts
from seven patients with multiple system atrophy (MSA) and (b) substantia nigra extracts from five patients with Parkinson’s disease (PD).
Cerebellum from a neurologically unaffected individual served as control. Five MSA cases were of the parkinsonian type (MSA-P) and two cases of
the cerebellar type (MSA-C). Assembled recombinant human α-synuclein was also injected (c)
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As a negative control, cerebellar extract from a 64 year old
neurologically normal individual was injected into 4
heterozygous M83 mice. At 18months of age, there were
no motor symptoms or staining for pS129 α-synuclein.
Dot blotting showed that the levels of α-synuclein phos-
phorylated at S129 varied between cases (Fig. 2). Thus,
approximately 1 ng assembled α-synuclein from MSA case
7 had a similar effect as approximately 85 ng from MSA
case 1. However, this was unlikely to account for the
differences between MSA and PD. The levels of assembled
α-synuclein of MSA cases 2 and 3 were similar to those of
PD cases 1 and 2.
α-Synuclein pathologies of PD and MSA can be
distinguished by silver staining [49]. PD pathology is
stained by Campbell-Switzer, but not Gallyas silver. By
contrast, MSA pathology is stained by both Campbell-
Switzer and Gallyas silver. We confirmed these find-
ings (Table 3; Fig. 3). Cases of PD were positive for
Campbell-Switzer, but not Gallyas, whereas all cases of
MSA were positive for both silver stains. Like PD,
brain and spinal cord from homozygous M83 mice
were positive for Campbell-Switzer, but negative for
Gallyas silver (Table 3; Fig. 3). Tissue sections from
heterozygous M83 mice were silver-negative.
Intracerebral injection of brain extracts from all cases
of MSA and most cases of PD, as well as injection of as-
sembled recombinant human α-synuclein, into heterozy-
gous M83 mice resulted in staining for pS129-α-
synuclein and motor dysfunction, leading to hindlimb
paralysis (Figs. 1, 4 and 5). α-Synuclein inclusions were
stained with Campbell-Switzer silver, but not Gallyas sil-
ver, irrespective of the injected material (Table 4; Fig. 6).
Discussion
Intracerebral injection of cerebellar homogenates from 7
cases of MSA into heterozygous mice transgenic for hu-
man mutant A53T α-synuclein caused the formation of
abundant neuronal α-synuclein inclusions and severe
motor dysfunction. Most cases of MSA can be divided
into MSA-P, a parkinsonian variant, and MSA-C, a cere-
bellar variant, based on the predominant motor symp-
toms [17, 29]. We injected brain extracts from 5 cases of
MSA-P and 2 cases of MSA-C and did not observe any
differences between cases. Future studies will have to
look at additional cases of MSA-P and MSA-C. The time
between injection and death was 167 ± 17 days. These
findings confirm previous studies of MSA brain extract
injections into the same mouse line [40, 52].
Unlike the earlier studies, which failed to observe a
motor phenotype following intracerebral injection of
PD homogenates [40], we observed neuronal α-
synuclein inclusions and hindlimb paralysis in 7 of 17
mice injected with substantia nigra extracts from 5 PD
patients. The time between injection and death was
286 ± 62 days. Five additional mice showed some α-
synuclein inclusions, but no motor impairment at 18
months of age. Five mice failed to develop either inclu-
sions or motor dysfunction. These results indicate that
α-synuclein assembly preceded neurodegeneration.
They are in agreement with previous studies showing
that α-synuclein inclusions from PD and DLB brains
exhibit prion-like behaviour [28, 41].
MSA homogenates were more potent than PD homoge-
nates, consistent with the view that α-synuclein assemblies
from MSA and PD are made of different conformers
[38, 40, 52]. Negative stain electron microscopy
Fig. 2 Dot blotting was used to measure the levels of pS129 α-
synuclein in cerebellar extracts from the seven cases of multiple
system atrophy (MSA) and substantia nigra extracts from the five
cases of Parkinson’s disease (PD) that were used for intracerebral
injection. Recombinant α-synuclein phosphorylated at S129 was
used for the standard curves
Table 3 Silver staining of brain sections from multiple system
atrophy (MSA) and Parkinson’s disease (PD) patients. Cerebellum
was used for MSA cases 2, 3, 6, 7, brainstem for cases 4, 5 and
basal ganglia for case 1. Substantia nigra was used for PD cases
1, 3, 4, 5 and cingulate cortex for case 2
Human tissue Gallyas silver Campbell-Switzer silver
(1) MSA-P + +
(2) MSA-P + +
(3) MSA-P + +
(4) MSA-P + +
(5) MSA-P + +
(6) MSA-C + +
(7) MSA-C + +
(1) PD – +
(2) PD – +
(3) PD – +
(4) PD – +
(5) PD – +
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established differences between α-synuclein filaments
of DLB, MSA and PD [7, 43, 44, 46]. Previous work
using recombinant α-synuclein showed that it can as-
semble into distinct filament conformations that exert
differing effects [3, 37]. The structures of recombinant
human α-synuclein assembled under various conditions
also showed differences [20, 25, 48]. We do not know how
the structures of our recombinant α-synuclein assemblies
related to those reported by others [20, 25]. Structures of
α-synuclein filaments from human brain are not known. It
therefore remains to be seen how they relate to those
of assembled recombinant protein. The structures of
a
b
c
d
Fig. 3 Silver staining (Campbell-Switzer and Gallyas) of tissue sections from (a) brainstem of multiple system atrophy (MSA-P) case 4, (b)
substantia nigra of Parkinson’s disease (PD) case 5 and lumbar spinal cord of non-injected (c) homozygous (tgM83+/+) and (d) heterozygous
(tgM83+/−) mice transgenic for human mutant A53T α-synuclein. Only MSA sections were Gallyas-positive. They were also stained by Campbell-
Switzer, as were PD and tgM83+/+ sections. TgM83+/− sections were silver-negative. Scale bars, 50 μm
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b
d
Fig. 4 Immunohistochemistry for pS129-α-synuclein of lumbar spinal cord from heterozygous mice transgenic for human mutant A53T α-
synuclein that were injected with (a) cerebellar extract from multiple system atrophy (MSA-P) case 1, (b) substantia nigra extract from Parkinson’s
disease (PD) case 3 and (c) assembled recombinant human α-synuclein. (d) Spinal cord from a non-injected mouse was used as control. Scale
bars, 50 μm
a
c
b
d
Fig. 5 Immunohistochemistry for pS129-α-synuclein of midbrain from heterozygous mice transgenic for human mutant A53T α-synuclein that
were injected with (a) cerebellar extract from multiple system atrophy (MSA-P) case 1, (b) substantia nigra extract from Parkinson’s disease (PD)
case 3 and (c) assembled recombinant human α-synuclein. (d) Midbrain from a non-injected mouse was used as control. Scale bars, 50 μm
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3R tau filaments from Pick’s disease are different from
those formed by incubating recombinant 2N3R tau with
heparin [10, 54].
We quantified the amount of assembled α-synuclein
in brain homogenates using dot blotting and an anti-
body specific for pS129-α-synuclein. Even though it
has been reported that GCI-α-synuclein is less phos-
phorylated at S129 than Lewy body α-synuclein [38],
the varying amounts of phosphorylated protein were
unlikely to account for the differences in motor
dysfunction that we observed between MSA and PD.
Injection of as little as 1 ng assembled pS129-reactive
α-synuclein was sufficient to cause motor dysfunction
in heterozygous M83 mice 5 months later. However,
this value may have been an underestimate, since some
seed-competent species of assembled α-synuclein may
not be phosphorylated at S129 [14].
Although the filamentous inclusions of PD and MSA
are made of assembled α-synuclein, they can be distin-
guished by silver staining. Both types of inclusion stain
with Campbell-Switzer, but only GCIs are also Gallyas-
positive. This difference may reflect the presence of
distinct conformers of assembled α-synuclein. It is
reminiscent of tau filaments from Alzheimer’s disease,
which are Campbell-Switzer and Gallyas-positive and
those from Pick’s disease, which are only Campbell-
Switzer-positive [50]. Electron cryo-microscopy has
shown that these filaments are made of different con-
formers of assembled tau [10, 12].
Upon intracerebral injection of MSA and PD brain
homogenates into heterozygous mice transgenic for
human mutant A53T α-synuclein, inclusions were
Campbell-Switzer-positive, but Gallyas-negative, like
those in homozygous mice. A recent study has also
shown that the inclusions formed following intracere-
bral injection of MSA brain extracts were Gallyas-
negative [9]. Injection of assembled recombinant
human α-synuclein gave rise to Campbell-Switzer-posi-
tive, Gallyas-negative α-synuclein inclusions. Cerebellar
extract from a neurologically normal individual was with-
out effect. These findings differ from those obtained fol-
lowing the injection of brain extract from APP/PS1 into
APP23 transgenic mice, when the seeds determined the
properties of the seeded aggregates [22].
α-Synuclein seeds from MSA and PD brains were from
end-stage disease. The mechanisms resulting in seed for-
mation at the beginning of the pathological process are
unknown. This is particularly relevant for MSA, which is
defined by the presence of abundant GCIs, despite the
fact that α-synuclein is expressed at best at only low
levels in oligodendrocytes and that assembly is
concentration-dependent [2, 30]. α-Synuclein may give
rise to a seed in as little as a single oligodendrocyte.
Seeded aggregation could then proceed, even though
oligodendrocytes express only low levels of α-synuclein.
Assemblies have been shown to spread between
oligodendrocytes [38]. The reason why GCIs were not
observed following intracerebral injection of MSA brain
extracts may have been due to the lack of significant
transgene expression in oligodendrocytes. It remains to
be seen if the A to T mutation at residue 53 of human
α-synuclein also played a role. It will be interesting to
Table 4 Silver staining of sections from the central nervous system of heterozygous mice transgenic for human mutant A53T α-
synuclein (tgM83+/−) following intracerebral injection of cerebellar homogenates from cases of multiple system atrophy (MSA) and
substantia nigra homogenates from cases of Parkinson’s disease (PD). Sagittal brain sections encompassed brainstem, hippocampus
and cerebral cortex. Spinal cord sections were of the lumbar region
Mouse Human brain extract Gallyas silver Campbell-Switzer silver
tgM83 +/+ – – +
tgM83 +/− – – –
tgM83 +/− (1) MSA-P – +
tgM83 +/− (2) MSA-P – +
tgM83 +/− (3) MSA-P – +
tgM83 +/− (4) MSA-P – +
tgM83 +/− (5) MSA-P – +
tgM83 +/− (6) MSA-C – +
tgM83 +/− (7) MSA-C – +
tgM83 +/− (1) PD – +
tgM83 +/− (2) PD – +
tgM83 +/− (3) PD – +
tgM83 +/− (4) PD – +
tgM83 +/− (5) PD – +
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determine the silver staining properties of the neuronal
and oligodendroglial α-synuclein inclusions that have
been described in cases of PD and DLB caused by muta-
tions in SNCA [21, 24, 27, 36].
In conclusion, the present findings show that the silver
staining properties of assembled α-synuclein in nerve
cells following intracerebral injection of PD and MSA
brain homogenates depend on both transgene expression
and its cellular environment.
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Fig. 6 Silver staining (Campbell-Switzer and Gallyas) of lumbar spinal cord from heterozygous mice transgenic for human mutant A53T α-
synuclein that were injected with (a) cerebellar extract from multiple system atrophy (MSA-P) case 1, (b) substantia nigra extract from Parkinson’s
disease (PD) case 3 and (c) assembled recombinant human α-synuclein. Scale bars, 50 μm
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